^
Association details:
| Biomarker: | RAS mutation |
|---|---|
| Cancer: | Thyroid Gland Carcinoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1743MO - MERAIODE: A redifferentiation phase II trial with trametinib followed by radioactive iodine for metastatic radioactive iodine refractory differentiated thyroid cancer patients with a RAS mutation
Published date:
09/13/2021
Excerpt:
Trametinib in RAS-mutated patients restores RAI uptake in a few patients and is followed by tumor response in 20% with limited adverse events
Trial ID:
